Hrt Financial LP Beam Therapeutics Inc. Transaction History

Hrt Financial LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$23.46 - $45.07 $656,270 - $1.26 Million	27,974 Added 280.27%	37,955 $1.25 Million
Q4 2023 Feb 09, 2024	BUY	$17.69 - $30.76 $176,563 - $307,015	9,981 New	9,981 $271,000
Q2 2022 Aug 12, 2022	SELL	$29.86 - $62.36 $622,461 - $1.3 Million	-20,846 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$53.73 - $82.16 $1.12 Million - $1.71 Million	20,846 New	20,846 $1.19 Million
Q3 2021 Nov 15, 2021	SELL	$84.37 - $133.6 $154,143 - $244,087	-1,827 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$64.12 - $128.71 $409,983 - $822,971	-6,394 Reduced 77.78%	1,827 $235,000
Q1 2021 May 17, 2021	BUY	$71.28 - $120.75 $585,992 - $992,685	8,221 New	8,221 $658,000

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.